Other languages Ocuphire Pharma, Inc.

Equities

OCUP

US67577R1023

Real-time Estimate Cboe BZX Other stock markets 03:26:59 2024-05-15 pm EDT			5-day change	1st Jan Change
1.755 ^USD	+3.24%		-3.83%	-41.53%

May. 10	Ocuphire Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 11	Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ocuphire Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10
Ocuphire Pharma Enrolls 1st Patient in Phase 3 Trial of Visual Acuity Treatment	Apr. 11
Ocuphire Pharma, Inc. Announces Global License Agreement with Viatris Inc	Apr. 11
Ocuphire Pharma, Inc. Announces the Enrollment of the First Subject in the LYNX-2 Phase 3 registration study	Apr. 11
Ocuphire Pharma, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 08
Ocuphire Pharma Appoints CFO, Science Chief	Feb. 14
Ocuphire Pharma, Inc. Announces Appointments of Ash Jayagopal, Ph.D., M.B.A. as Chief Scientific and Development Officer	Feb. 14
Ocuphire Pharma, Inc. Announces Presentation of Clinical Data from Its ZETA-1 Trial on A Person-Level Scale Evaluating APX3330 in Diabetic Retinopathy	Feb. 05
Ocuphire Pharma, Inc. Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity Under Dim Light Conditions	Jan. 04
Ocuphire Pharma, Inc. Promotes Ronil Patel to Chief Business Officer, Effective as of December 1, 2023	Dec. 06
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer	Nov. 27
Ocuphire Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Ocuphire Pharma, Inc. Announces Successful End-Of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy	Nov. 02
Ocuphire Pharma Appoints George Magrath as Chief Executive	Nov. 01
Ocuphire Pharma, Inc. Appoints George Magrath as Member of Board of Directors	Nov. 01
Ocuphire Pharma, Inc. Announces Chief Executive Officer Changes	Nov. 01
Viatris, Ocuphire Pharma Say US FDA Approves Eye Drops to Treat Pharmacologically-Induced Dilation of Pupils	23-09-27
Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl?? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents	23-09-27
Ocuphire Pharma Gets FDA Approval for Ryzumvi Opthlamic Solution, FDA Website Shows	23-09-26
Ocuphire Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Ocuphire Pharma, Inc.

Equities

OCUP

US67577R1023

Other languages

Filters